Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sale
Corcept Therapeutics shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates. Also, HC Wainwright raised its price target on the stock from $95 to $165.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.